Compugen (CGEN) Net Cash Flow (2009 - 2010)
Compugen (CGEN) reported Net Cash Flow of $3.0 million for Q4 2010, down 68.11% on a YoY basis from $9.5 million in Q4 2009, and up 139.57% sequentially from -$7.6 million in Q3 2010.
Compugen (CGEN) Net Cash Flow (2009 - 2010) Analysis & Trends
Compugen (CGEN) has 2 years of Net Cash Flow data on file, last reported at $3.0 million in Q4 2010.
- For the quarter ending Q4 2010, Net Cash Flow fell 68.11% year-over-year to $3.0 million; the trailing twelve-month figure through Sep 2011 stood at $3.0 million (up 64.35% YoY), and the FY2025 full-year result was $72.2 million, up 1749.28% from the prior year.
- Net Cash Flow climbed to $3.0 million in Q4 2010, from -$7.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $9.5 million in Q4 2009 to a low of -$7.6 million in Q3 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 3.02 Mn |
| Dec 31, 2010 | 3.02 Mn |
| Sep 30, 2010 | -7.64 Mn |
| Sep 30, 2010 | -7.64 Mn |
| Dec 31, 2009 | 9.48 Mn |
| Dec 31, 2009 | 9.48 Mn |
| Sep 30, 2009 | -935,000.00 |
| Sep 30, 2009 | -935,000.00 |